Women's Health · LP-109
Misoprostol Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-109Women's Health
- Generic identity
- MisoprostolTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-109
- Generic ingredient
- Misoprostol
- Dosage form
- Tablet
- Proposed strength
- 200 mcg
- Proposed pack
- Blister 4 or 10 tablets
- Portfolio category
- Women's Health
About Misoprostol
Misoprostol is a prostaglandin analogue with effects on the gastrointestinal tract and uterus. It appears in different clinical contexts internationally, including prevention of certain medicine-related gastric ulcers and reproductive or obstetric care governed by specific protocols. Those contexts have materially different eligibility requirements and safety considerations. This public catalogue provides high-level ingredient education, without a regimen or an instruction for any pregnancy-related use.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
A treating professional must establish the intended indication, assess pregnancy where relevant and apply current local law, authorization and clinical guidance. General ulcer-prevention labeling is not a substitute for a reproductive-health protocol, and neither should be copied wholesale to an unverified product page. Pregnancy-related care also requires assessment of clinical circumstances and access to appropriate follow-up or emergency care. The catalogue does not confirm any local marketing authorization or approved route.
Important safety considerations
Diarrhoea, abdominal pain, cramping, nausea and fever can occur. Uterine effects can cause pregnancy loss, heavy bleeding or serious obstetric complications in relevant settings. Prior uterine surgery, gestational circumstances and unexplained pain or bleeding require professional assessment. Misoprostol does not diagnose or treat ectopic pregnancy. Severe bleeding, collapse, persistent severe pain or signs of infection require urgent care. The selected warnings are not a complete contraindication list.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The source describes tablets in blister packs. Moisture protection and packaging performance are especially relevant considerations, but no shelf life, storage limit or alternative administration route is established here. Exact product instructions must come from the authorized label.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm the indication, applicable local authorization, pregnancy-related clinical factors when relevant, follow-up arrangements and access to urgent care. Supply decisions require verified product documentation.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Misoprostol
- Dosage form / presentation
- Tablet
- Catalogue strength
- 200 mcg
- Catalogue pack
- Blister 4 or 10 tablets
- Portfolio category
- Women's Health
Layer 02
Unresolved product-specific fields
- The catalogue establishes a 200 mcg tablet and pack sizes only. It does not establish an authorised clinical indication, regimen, patient group or any non-oral administration method.
- Tablet coating, excipients, moisture-protection requirements and formulation-specific handling remain product-specific.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Misoprostolgovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming exact active chemical form, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-109, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-109.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.